DEXA scans are invaluable for detecting this imbalance, as they provide a detailed breakdown of fat and lean tissue
The study results of the studies SURPASS-1 to SURPASS-5 have been published, and the remaining studies (SURPASS-6, SURPASS-CVOT, SURPASS-J-mono, SURPASS-J-combo
Semin Pediatr Surg 27:237241
These are the factors that typically point toward the slower path: Prior intolerable nausea or vomiting on semaglutide, tirzepatide, or other GLP-1 medications History of GERD, gastroparesis, or functional GI disorders Lower body weight, where the effective dose-per-kilogram is relatively higher at standard doses First-time users of peptide or GLP-class medications with no tolerability baseline The slow-titration approach does not change the target dose or the expected outcomes
Not for diagnostic, therapeutic, or consumer applications
Spending 6 to 8 weeks at each dose instead of 4 gives the body more time to adapt while maintaining the pharmacokinetic profile that the clinical trials validated
